Nehad Mohamed Elshatby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nehad Mohamed Elshatby has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Abeer Abdel Moniem Shahba
Rheumatology & Clinical Immunology Unit, Department of Internal Medicine, Faculty of Medicine, Tanta University, Tanta 31527, Egypt
1 shared publication Ahmed S. EL Mahallawy
Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Alexandria University, Alexandria, Egypt
1 shared publication- Ahmed Yehia Ismaeel
Internal Medicine Department, Faculty of Medicine, Beni-Suef University, Beni-Suef 62511, Egypt
1 shared publication - Dina Shahin
Rheumatology & Immunology Unit, Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt
1 shared publication - Eiman Soliman
Rheumatology & Immunology Unit, Department of Internal Medicine, Alexandria University, Alexandria, Egypt
1 shared publication - Eman F. Mohamed
Rheumatology Unit, Internal Medicine Department, Faculty of Medicine (Girls), Al-Azhar University, Cairo 11651, Egypt
1 shared publication
Latest Publications
- Open Access
- 17 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 7241
Real-World Effectiveness and Safety of Anifrolumab in Egyptian Patients with Moderate-to-Severe Systemic Lupus Erythematosus: A Retrospective Multicenter Study
Background and Objectives: Real-world data on anifrolumab in Egyptian patients with moderate-to-severe systemic lupus erythematosus (SLE) remain limited. This study aimed to evaluate the real-world effectiveness and safety of anifrolumab in Egyptian patients with moderate-to-severe SLE. Materials and Methods: This retrospective, multicenter, observational cohort study reviewed the medical records of 80 adults with moderate-to-severe SLE who had received at least 6 doses (≥20 weeks) of intravenous anifrolumab 300 mg every 4 weeks as part of routine clinical care at 13 Egyptian tertiary rheumatology centers; medical record review and data extraction were performed between May and July 2026. Outcomes were assessed at baseline and final follow-up and included disease activity, lupus low disease activity state (LLDAS), glucocorticoid use, flare status, laboratory parameters, and adverse events. Results: Patients were predominantly female (98.8%), with a mean age of 30.4 ± 9.8 years. Disease activity improved, with SLEDAI-2K decreasing from 11 to 4 (p < 0.001), PGA from 2.7 to 0.5 (p < 0.001), LLDAS increasing from 0% to 51.3% (p < 0.001), and flares decreasing from 95.0% to 18.8% (p < 0.001). Glucocorticoid burden also declined, with oral glucocorticoid use falling from 95.0% to 83.8% (p = 0.021), median prednisone dose from 20 mg/day to 5 mg/day (p < 0.001), intravenous methylprednisolone use from 50.0% to 6.3% (p < 0.001), and 63.8% achieving prednisone doses ≤ 7.5 mg/day (p < 0.001). Laboratory improvement included hemoglobin, leukocyte count, lymphocyte count, platelet count, C3, C4, anti-dsDNA, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), while serum creatinine did not change significantly (p = 0.904). No serious adverse events were reported. Conclusions: Anifrolumab was associated with significant short-term improvement in clinical and laboratory disease activity, marked steroid sparing, and reduced flare burden in Egyptian patients with moderate-to-severe SLE, with acceptable short-term tolerability.
- 17 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 7241
Open AccessReal-World Effectiveness and Safety of Anifrolumab in Egyptian Patients with Moderate-to-Severe Systemic Lupus Erythematosus: A Retrospective Multicenter Study
Background and Objectives: Real-world data on anifrolumab in Egyptian patients with moderate-to-severe systemic lupus erythematosus (SLE) remain limited. This study aimed to evaluate the real-world effectiveness and safety of anifrolumab in Egyptian patients with moderate-to-severe SLE. Materials and Methods: This retrospective, multicenter, observational cohort study reviewed the medical records of 80 adults with moderate-to-severe SLE who had received at least 6 doses (≥20 weeks) of intravenous anifrolumab 300 mg every 4 weeks as part of routine clinical care at 13 Egyptian tertiary rheumatology centers; medical record review and data extraction were performed between May and July 2026. Outcomes were assessed at baseline and final follow-up and included disease activity, lupus low disease activity state (LLDAS), glucocorticoid use, flare status, laboratory parameters, and adverse events. Results: Patients were predominantly female (98.8%), with a mean age of 30.4 ± 9.8 years. Disease activity improved, with SLEDAI-2K decreasing from 11 to 4 (p < 0.001), PGA from 2.7 to 0.5 (p < 0.001), LLDAS increasing from 0% to 51.3% (p < 0.001), and flares decreasing from 95.0% to 18.8% (p < 0.001). Glucocorticoid burden also declined, with oral glucocorticoid use falling from 95.0% to 83.8% (p = 0.021), median prednisone dose from 20 mg/day to 5 mg/day (p < 0.001), intravenous methylprednisolone use from 50.0% to 6.3% (p < 0.001), and 63.8% achieving prednisone doses ≤ 7.5 mg/day (p < 0.001). Laboratory improvement included hemoglobin, leukocyte count, lymphocyte count, platelet count, C3, C4, anti-dsDNA, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), while serum creatinine did not change significantly (p = 0.904). No serious adverse events were reported. Conclusions: Anifrolumab was associated with significant short-term improvement in clinical and laboratory disease activity, marked steroid sparing, and reduced flare burden in Egyptian patients with moderate-to-severe SLE, with acceptable short-term tolerability.
- Open Access
- 2 February 2026
- Published by Springer Nature in BMC Oral Health
- Vol. 26 (1)
Customized z-shaped versus conventional miniplates for fixation of parasymphyseal/body mandibular fractures: a randomized controlled trial evaluating clinical and radiographic outcomes
Background: Mandible is considered the protrudest mobile bone of the facial skeleton so it is the most common maxillofacial fracture. Customized Z miniplate is a new geometry that may provide better mental nerve preservation, healing of fractures compared with conventional two miniplates in the treatment of parasymphyseal/body mandibular fractures. Aim of the study: To compare between customized Z miniplates and conventional miniplates for fixation of parasymphyseal and body mandibular fractures in terms of bone density (primary outcome), post operative mental nerve paresthesia, pain, occlusion and operation time (secondary outcomes). Materials and methods: This prospective, parallel, exploratory, randomized controlled study was conducted from April to December 2024 and included 22 patients diagnosed with parasymphyseal or body mandibular fractures. Allocation (customized Z-miniplates, n = 11; two miniplates, n = 11) was done by independent statistician using a computer-generated random number list method. Mann-Whitney U, Wilcoxon-signed rank and Chi-square tests were applied ( p < 0.05). Postoperative patient evaluation was done for primary outcome (bone density) and for secondary outcomes (nerve paresthesia, postoperative pain, occlusion and operation time). All adverse events were recorded prospectively during follow-up visits. The trial was registered retrospectively at ClinicalTrials.gov (NCT07094867) due to administrative procedures, which represents a potential source of bias. Results: Statistical analysis did not detect significant variation in terms of mean bone density, occlusion, mental nerve affection and pain between customized Z miniplates and conventional two miniplates. Operation time was statistically significant shorter in customized Z miniplate group ( p < 0.001). Only one case of wound dehiscence occurred in each group and no other complications observed. Conclusion: Both fixation methods provided results that were not statistically distinct in terms of pain, occlusion, mental nerve affection and mean bone density, with significant shorter operation time for parasymphyseal/body mandibular fracture fixation. Given the sample size, our study provides preliminary findings of clinical and radiographical performance of customized Z plate. Trial registration: The research was formally recorded in the clinicaltrials.gov database with registration submitted on 06/27/2025 under the number (NCT07094867).
- 2 February 2026
- Published by Springer Nature in BMC Oral Health
- Vol. 26 (1)
Open AccessCustomized z-shaped versus conventional miniplates for fixation of parasymphyseal/body mandibular fractures: a randomized controlled trial evaluating clinical and radiographic outcomes
Background: Mandible is considered the protrudest mobile bone of the facial skeleton so it is the most common maxillofacial fracture. Customized Z miniplate is a new geometry that may provide better mental nerve preservation, healing of fractures compared with conventional two miniplates in the treatment of parasymphyseal/body mandibular fractures. Aim of the study: To compare between customized Z miniplates and conventional miniplates for fixation of parasymphyseal and body mandibular fractures in terms of bone density (primary outcome), post operative mental nerve paresthesia, pain, occlusion and operation time (secondary outcomes). Materials and methods: This prospective, parallel, exploratory, randomized controlled study was conducted from April to December 2024 and included 22 patients diagnosed with parasymphyseal or body mandibular fractures. Allocation (customized Z-miniplates, n = 11; two miniplates, n = 11) was done by independent statistician using a computer-generated random number list method. Mann-Whitney U, Wilcoxon-signed rank and Chi-square tests were applied ( p < 0.05). Postoperative patient evaluation was done for primary outcome (bone density) and for secondary outcomes (nerve paresthesia, postoperative pain, occlusion and operation time). All adverse events were recorded prospectively during follow-up visits. The trial was registered retrospectively at ClinicalTrials.gov (NCT07094867) due to administrative procedures, which represents a potential source of bias. Results: Statistical analysis did not detect significant variation in terms of mean bone density, occlusion, mental nerve affection and pain between customized Z miniplates and conventional two miniplates. Operation time was statistically significant shorter in customized Z miniplate group ( p < 0.001). Only one case of wound dehiscence occurred in each group and no other complications observed. Conclusion: Both fixation methods provided results that were not statistically distinct in terms of pain, occlusion, mental nerve affection and mean bone density, with significant shorter operation time for parasymphyseal/body mandibular fracture fixation. Given the sample size, our study provides preliminary findings of clinical and radiographical performance of customized Z plate. Trial registration: The research was formally recorded in the clinicaltrials.gov database with registration submitted on 06/27/2025 under the number (NCT07094867).